Slide 1: Orion Group Financial Review Proforma 1-12/2006
Orion Group Financial Review Proforma 1-12/2006 6 February 2007 7-12/2006 was the first official financial accounting period of the present Orion. The figures for 1-6/2006 and the years 2004 and 2005 have been carved out from the financial statements of the demerged Orion. Orion Corporation AA, Comm
Slide 2: 13 key global pharma markets in 11/2005–10/2006
13 key global pharma markets in 11/2005 –10/2006 Source: IMS Health Retail Drug Monitor 12/2006 Pharma sales Change on 11/05 - 11006 comparative Break- USD billion period down North America 208,4 +7 % 54 % Europe top 5 93,3 +4 % 24 % Japan 56,8 +1 % 15 % Latin America top 3 19,0 +12 % 5% Australia /
Slide 3: Finnish pharmaceutical market in 2006
Finnish pharmaceutical market in 2006 • Total pharmaceutical wholesales were EUR 1,727 million, same as in the comparative period (change -0.8%). • Wholesales of Orion’s pharmaceutical products were EUR 152.4 million, -10.7% down from 2005. – The value of wholesales is depressed by • 5% price cut in
Slide 4: Orion key figures 2004–2006
Orion key figures 2004 –2006 2004 2005 2006 Change Proforma Proforma Proforma % Net sales, EUR m 553,0 585,6 641,1 +9,5% Operating profit, EUR m 105,3 155,2 196,7 +26,7% % of net sales 19,0% 26,5% 30,7% Profit before taxes, EUR m 104,1 154,3 197,3 +27,9% Earnings per share, EUR 0,55 0,83 1,03 +24,7%
Slide 5: Group EBIT by annual quarters; Balance Sheet
Group EBIT by annual quarters No milestone payments have been received in the periods EUR m 70 62,9 60 54,3 50 45,3 45,9 42,9 38,1 40 36,6 25,9 30 20 10 0 1-3/'05 4-6/'05 7-9/'05 10-12/'05 1-3/'06 4-6/'06 7-9/'06 7-12/'06 Orion Corporation AA, Communications 6.2.2007 9 Balance Sheet EUR m 605,1 588,
Slide 6: Orion B share performance and ownership base
Orion B in relation to OMX Portfolio and Europe Pharmaceutical indeces 3 July –2 February 2007 130 2.2.2007 Orion B 124,68 OMXH Portfolio 121,47 120 Europe Pharmaceutical 101,58 110 3.7.2006 = 100 100 90 80 3.7.2006 3.8.2006 3.9.2006 3.10.2006 3.11.2006 3.12.2006 3.1.2007 Orion Corporation AA, Commu
Slide 7: Net sales and EBIT 1-12/2006 by business segments
Net sales and EBIT 1-12/2006 by business segments Net sales EBIT Proforma Proforma EUR m Change EUR m Change Pharmaceuticals 601,4 +9,9% 189,9 +22,8% Diagnostics 41,5 +1,8% 6,6 +5,1% Group items -1,8 -14,8% 0,2 -103,5% Group total 641,1 +9,5% 196,7 +26,7% Orion Corporation AA, Communications 6.2.200
Slide 8: Net sales by geographic segments; Pharmaceuticals business 1-12/2006
Net sales by geographic segments in 2006 Other markets 8% North America Finland 13% 29% Scandinavia Other Europe 14% 36% Net sales total EUR 641.1 million Orion Corporation AA, Communications 6.2.2007 15 Pharmaceuticals business 1-12/2006 2005 2006 EUR m Change Proforma Proforma Net sales 547,0 601,
Slide 9: 10 best-selling drugs of Orion in 2006
10 best-selling drugs of Orion in 2006 EUR m 2006 Change EUR 304.5 million, Proforma on 2005 51% of total pharmaceutical Stalevo (Parkinson’ s disease) 111,3 +49,1% net sales Fareston Comtess / Comtan (Parkinson) 74,7 +5,8% Calcimagon Domitor, Domosedan, Antisedan 26,0 -0,0% Burana Stalevo (animal s
Slide 10: Entacapone franchise sales; Pharmaceutical research projects
Quarterly net sales from the entacapone franchise 2002 –2006, by products 60 EUR m 50 40 Stalevo 30 Comtess+ 20 Comtan Enta total 10 0 02 02 02 03 03 03 04 05 05 05 06 06 02 03 04 04 04 05 06 06 1/ 2/ 2/ 3/ 2/ 3/ 4/ 1/ 3/ 4/ 1/ 2/ 3/ 4/ 1/ 3/ 4/ 1/ 2/ 4/ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Orion
Slide 11: Situation of the Simdax project; Pharmaceutical R&D portfolio
Situation of the Simdax (i.v. levosimendan) project • Orion Corporation and Abbott are continuing negotiations concerning a possible additional Phase 3 clinical study with i.v. levosimendan (Simdax). The two companies are also discussing on the sharing of the costs of the possible study. Orion has a
Slide 12: Diagnostics business in 1-12/2006; Outlook for 2007
Diagnostics business in 1-12/2006 2005 2006 EUR m Change Proforma Proforma Net sales 40,8 41,5 +1,8% Operating profit 6,3 6,6 +5,1% • Net sales growth remained low owing to the flat development in the second half of the year. • In-focus products, such as the QuikRead® CRP tests and the UniQue® colla
Slide 13: Financial objectives and Dividend policy; Proposed dividend
Financial objectives and Dividend policy Financial objectives • The moderate organic growth of the net sales in the next few years is accelerated via product, portfolio and company acquisitions. • Operating profit will be increased • Equity ratio is maintained at the level of at least 50%. Dividend
Slide 14: Other matters on the AGM agenda; Executive Management
Other matters on the agenda of the AGM on 2 April 2007 • The proposed number of members of the Board of Directors is six. Eero Karvonen, Matti Kavetvuo, Leena Palotie and Vesa Puttonen are proposed to be re-elected. Hannu Syrjänen and Jukka Ylppö are proposed to be elected as new members. • Matti Ka
Slide 15: Orion's reporting schedule in 2007
Orion’ s reporting schedule in 2007 Annual Report Week 10/2007 AGM Monday 2 April 2007 Interim Report 1-3/2007 Wednesday 25 April 2007 Interim Report 1-6/2007 Monday 6 August 2007 Interim Report 1-9/2007 Wednesday 24 October 2007 Orion Corporation AA, Communications 6.2.2007 29 Orion Corporation AA,